TRAV1-1

Across TCGA pan-cancer cohorts, TRAV1-1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV1-1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRAV1-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV1-1 expression acts as an unfavorable survival marker.

BLCA, LUSC, and SKCM are the cancer types where TRAV1-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.018	0.720	<.001	24	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRAV1-1–BLCA (OS)

Open the BLCA breakdown →